News: AHZ Admedus Says Cardiocel 3D And Vascucel Receives European Regulatory Approval, page-450

The MC value is that of a start-up biotech stock anyway, so you should treat the stock as such....but with $30M in revenue, it makes this stock a very interesting prospect, don't you think??

And the 2 extremely big share holders don't seem to be exiting anytime soon given they did participate in the CR at 8c+, and I think it's because of this significant revenue and new IP in the pipeline, they are sticking around and seeing a recovery...soon.